Table 2 Molecular mass of immunoprecipitated TTR (Da, mean ± SD) assigned to different forms1 of TTR between serum and ascitic fluid of 20 representative women with ovarian cancer. Values in brackets represent mass differences of modified TTR in relationship to the native form of TTR (Da, mean ± SD).
From: Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients
TTR | cysTTR | cysglycTTR | glutTTR | |
|---|---|---|---|---|
serum | 13757.7 ± 7.1 | 13875.8 ± 12.8 (118.1 ± 13.7) | 13923.6 ± 21.0 (166.8 ± 20.9) | 14062.1 ± 24.7 (306.4 ± 23.9) |
ascitic fluid | 13752.7 ± 16.5 | 13876.9 ± 13.3 (124.2 ± 13.7) | 13926.8 ± 11.1 (176.8 ± 1.8) | 14042.5 ± 27.0 (294.6 ± 22.7) |